Clinical trial
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced…
NCT00088556 · Telik, Industry · Completed
Key facts
| NCT number | NCT00088556 |
|---|---|
| Title | Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer |
| Official title | Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin, Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Telik, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | TLK286, carboplatin, paclitaxel |
| Enrollment | 100 |
| Start date | Aug 1, 2004 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Jul 30, 2004 |
| Last update posted | May 31, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: